The October 14, 2026, Form 4 filing is an SEC report of insider stock activity. It lists Lin Shao-Lee as chief executive officer of Cue Biopharma (CUE). Both transactions took place on October 12, two days before the filing date.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-12 |
| Date of Latest Transaction | 2026-10-12 |
| Buy/Sell | sell |
| Transaction Count | 2 |
| Shares Transacted | 11,087 |
| Price | $27.55 |
| Total Transaction Value | $305,490.35 |
| Insider | |
| Ticker Symbol | CUE |
| Company | Cue Biopharma, Inc. |
| Insider Name | Lin Shao-Lee |
| Insider Title | Chief Executive Officer |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 694,908 |
| Position Size Change | 1.57% |
| Filing | |
| Filing Date | 2026-10-14 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported with SEC transaction code S. The record covers two transactions by one insider in a single filing.
What was the average price of the transaction?
The average sale price was $27.55 per share, rounded to the nearest cent. That is the average across both transactions; separate prices for each sale are not available.
How did this transaction affect the insider's holdings?
Lin Shao-Lee sold 11,087 shares and reported owning 694,908 shares afterward. The shares sold made up 1.57% of the shares held before the sales.
What's the total transaction value?
The total value was $305,490.35. This amount covers both reported sale transactions.
Are there any special circumstances around this transaction?
The sales were identified as linked to taxes or the cost of using a stock option. A stock option gives someone the right to buy shares at a set price.
No filing footnote text was available to explain the link. The details do not confirm that an option was used or that taxes were the only purpose. Code S identifies these transactions as sales, rather than shares held back or handed over to settle a bill.
For research purposes only; not investment advice.